GB Sciences Completes Harvest of First Cannabis Crop in Partnership with The Louisiana State University Agricultural Research Center

Nationally recognized collaboration with the Louisiana State University Agricultural Center

LAS VEGAS, January 16, 2019/PR Newswire/– GB Sciences, Inc. (OTCQB: GBLX) announced the harvest of the first test cannabis crop in the company’s nationally-recognized collaboration with Louisiana State University Agricultural Center.

On November 16, the Louisiana Department of Agriculture and Forestry took possession of extract samples for testing and expects to complete testing by mid-February. Once GBSL extract passes two tiers of tests, the company will make available the first-ever legal cannabis products to Louisiana patients.

“This harvest is a major milestone. Raw material for the first legal cannabis products are being tested, and Louisiana patients suffering from cancer, Parkinson’s, epilepsy, intractable pain and more are closer to relief,” said GBSL President John Davis. “I’m confident our state-of-the-art operations and collaboration with the LSU Agricultural Center will result in passing test results, allowing us to produce final products for sale in nine licensed pharmacies. Today, Louisiana is a critical step closer to legal medical cannabis.” 

Under Louisiana law:

  • GBSL extract will now be tested by the Louisiana Department of Agriculture and Forestry for pesticides, residual solvents, heavy metals, and mycotoxins.
  • Following this testing, GBSL will begin the final phase of product formulation.
  • Final products will undergo secondary LDAF tests for microbiological contaminants, potency, and homogeneity.
  • Once cleared for sale, final products will be released to the state’s nine pharmacies for sale.

GBSL’s initial product release will be tinctures, an orally-digestible product. The company repopulated phase I of its cultivation facility. The larger phase II expansion is completed and awaits final LDAF approval before it can be fully populated with plants.

In 2017, GB Sciences won a competitive public bid process to partner with LSU Agricultural Center. LSU Agricultural Center is operating its therapeutic cannabis program under one of the two cultivation licenses issued in Louisiana. In this public-private partnership, GBSL is the cultivator and producer of therapeutic cannabis products for patients with qualifying medical conditions.

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:

About Louisiana State University Agricultural Center

The Louisiana State University Agricultural Center (“LSU AgCenter” or “AgCenter”) is an institution under the supervision and management of the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (the “LSU Board of Supervisors”). The AgCenter’s mission is to provide the people of Louisiana with research-based educational information that will improve their lives and economic well-being. The LSU AgCenter includes the Louisiana Agricultural Experiment Station, which conducts Agricultural and Renewable Natural Resource-based research, and the Louisiana Cooperative Extension Service, which extends the knowledge derived from research to the people of the state. The LSU AgCenter plays an integral role in supporting agricultural industries, enhancing the environment, and improving the quality of life through its 4-H youth, family and consumer sciences, and community development programs.


Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information


GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or Liz Bianco, Director of Publicity,